The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
The industry rank for Bavarian Nordic AS's 14-Day RSI or its related term are showing as below:
CHIX:BAVAc's 14-Day RSI is ranked worse than 57.04% of 1420
companies
in the Biotechnology industry
Industry Median: 48.885
vs CHIX:BAVAc: 39.32
Bavarian Nordic AS (CHIX:BAVAc) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Bavarian Nordic AS 14-Day RSI Related Terms
CHIX:BAVAC vs VRTX, REGN, ALNY: 14-Day RSI Comparison
For the Biotechnology subindustry, Bavarian Nordic AS's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bavarian Nordic AS 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bavarian Nordic AS's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Bavarian Nordic AS's 14-Day RSI falls into.
Bavarian Nordic AS (CHIX:BAVAc) 14-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bavarian Nordic AS (CHIX:BAVAC) has a 14-Day RSI of 39.32 as of Jul. 12, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Bavarian Nordic AS and its competitors. According to the industry distribution chart, Bavarian Nordic AS ranks #810 out of 1420 companies in the Biotechnology industry, placing it in the top 57%.
Is Bavarian Nordic AS's 14-Day RSI too high?
Bavarian Nordic AS's current 14-Day RSI is 39.32. The Biotechnology industry median 14-Day RSI is 48.89. Bavarian Nordic AS's value of 39.32 is 19.6% below this industry median. Based on the distribution chart, Bavarian Nordic AS ranks #810 out of 1420 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Bavarian Nordic AS has a GF Score™ of 82/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bavarian Nordic AS's 14-Day RSI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bavarian Nordic AS ranks #810 out of 1420 companies for 14-Day RSI. This places Bavarian Nordic AS in the lower half of its industry. The industry median 14-Day RSI is 48.89. Bavarian Nordic AS's value of 39.32 is 19.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 48.89, based on 1,420 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bavarian Nordic AS's current 14-Day RSI of 39.32 is 19.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Bavarian Nordic AS and its competitors. For the Biotechnology industry, the median 14-Day RSI is 48.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bavarian Nordic AS's current 14-Day RSI is 39.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bavarian Nordic AS stock overvalued right now?
Based on GuruFocus' analysis, Bavarian Nordic AS (CHIX:BAVAC) is currently considered Modestly Overvalued. The stock's GF Value™ is kr166.22, compared to a current price of kr188.30 — trading 13.3% above its estimated fair value. The current 14-Day RSI is 39.32 and 19.6% below the Biotechnology industry median of 48.89. Bavarian Nordic AS's overall GF Score™ is 82/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Bavarian Nordic AS (CHIX:BAVAC), the current 14-Day RSI is 39.32 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bavarian Nordic AS (CHIX:BAVAC) Overvalued in 2026?
Based on GuruFocus' analysis, Bavarian Nordic AS stock appears to be overvalued.
The current stock price of kr188.30 is trading 13.3% above its estimated GF Value™ of kr166.22.
GuruFocus considers Bavarian Nordic AS to be Modestly Overvalued.
Key valuation signals for CHIX:BAVAC:
14-Day RSI: 39.32
GF Value™: kr166.22 vs. price of kr188.30 (13.3% above fair value)
Industry Position: 19.6% below the Biotechnology median (#810 of 1420)
No single metric tells the full story. See the CHIX:BAVAC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bavarian Nordic AS is a biotechnology company focused on the research, development, manufacturing, and commercialization of life-saving vaccines. The group is a supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and has a portfolio of travel vaccines. The vast majority of the company's revenue is generated in the United States, Germany, and other geographic markets. Its products include Encepur, Jynneos, Rabipur, Vaxchora, VIMKUNYA and Vivotif.
82GF Score
Get the complete analysis for CHIX:BAVAC
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:BAVAC has been successfully added to your 